RX modena and Randox Reagents used in COVID-19 hospital in India

Home - Reagents

RX modena and Randox Reagents used in COVID-19 hospital in India

News       RX modena       COVID-19

 

 

18 June 2020

RX modena and Randox Reagents used in COVID-19 hospital in India

Randox Laboratories has installed an RX modena into a COVID-19 hospital in India; the Netaji Subhash Chandra Bose Medical College in Madhya Pradesh state.

The installation, which marks the first RX modena to be used in an Indian Government Medical College, replaces existing instrumentation in the Medical College laboratory, an initiative which was driven by College Dean Dr. Pradeep Kumar Kasar and Head of Department Dr. Ashok Kumar Sahu.

The RX modena will cater for an additional 38 samples compared to the previous instrumentation, and is running a range of biochemistry tests that play a pivotal role in COVID-19 patient management, including C-Reactive Protein (CRP), Ferritin, and Lactate Dehydrogenase (LDH).

Dr. Ashok Kumar Sahu, Head of Biochemistry at Netaji Subhash Chandra Bose Medical College, commented;

“We are very pleased with the performance of the RX modena, and in particular with its wide menu of tests that can be utilized for COVID-19 patient management. Its high throughput and versatility have been a great support for the clinicians working in our COVID-19 hospital, in determining risk stratification, disease progression, and response to treatment.”

The RX modena is a high volume, floor standing, fully automated clinical chemistry analyser with a world leading test menu which covers specific proteins, lipids, therapeutic drugs, antioxidants, diabetes and veterinary testing. The versatile analyser offers advanced methodologies with excellent correlation to the gold standard, and excellent reagent CV ranges.

Shail Dholabhai, Randox India Sales Manager, commented;

 “We are delighted that the team at Netaji Subhash Chandra Bose Medical College have chosen the RX modena to fulfil the testing requirements of this COVID-19 hospital. Offering an unrivalled test menu of routine and specialized chemistries, the RX modena provides laboratories with the superior precision, reliability and accuracy that the Randox RX series is renowned for.

“Capable of performing a total of 1200 tests per hour including ISE, the RX modena presents a new class of efficiency which will result in faster and more accurate diagnoses, and ultimately, lead to better patient outcomes.”

Benefits of the RX modena

  • Capable of performing 800 photometric and a total of 1200 tests per hour including ISE.
  • World-leading extensive test menu covering routine chemistries, specific proteins, lipids, antioxidants, cardiac, diabetes and veterinary testing, offering cost savings through consolidation of routine and novel tests on a single platform.
  • Economic platform with low water consumption of less than 20 litres per hour saving on consumable costs. The RX modena also requires less than 5 minutes minimal maintenance.
  • Interactive touch-screen technology with integrated barcode readers for reagent and sample identification. Increased functionality with 13 wavelengths generated via diffraction grating (340-800nm) ensuring a multitude of chemistries are possible on one system.
  • Easy-to-use advanced Microsoft 10 software with a built-in Inventory Management System calculating the number of tests remaining, providing alerts of shortages and expired reagents and calibrators. The RX modena also features automatic test re-run function and sample dilution.
  • Dedicated reagent and sample pipettes to minimise the risk of errors and contamination. The RX modena also features a continuous loading hatch to allow for samples to be analysed quickly and easily during a run.
  • Advanced QC capabilities with daily, monthly and batch QC with data archiving, Levey-Jennings charts and automatic QC and calibration. There are also 7 different calibration options available.

For further information about the RX modena click here. 

For information about laboratory tools for COVID-19 patient management please click here.

For other enquiries please contact marketing@randox.com

 

Want to know more about Randox?

Contact us or visit our homepage to view more.

Our Randox Products and Services

REAGENTS

RX SERIES

ACUSERA

BIOCHIP


Open Channel Reagents

12 November 2019

Open Channel Reagents

There are many different manufacturers of clinical chemistry analysers, who provide their users with extensive test menus. However, it is very difficult for these manufacturers to meet every need in a clinical lab.

Open channel reagents can help to fill any gaps in these test menus, thus providing clinical laboratories with an alternative whilst securing controls and reagents that aren’t available from their instrument provider.

Open channel reagents give laboratories the ability to bring new diagnostic tests in-house and improve patient care by reducing turnaround times, which in the long run allows for faster diagnosis and quicker treatment plan decisions.

Although open channel reagents offer a very important service to clinical laboratories, it is imperative to carefully evaluate suppliers on the quality of their assays, as well as the service and support they provide – ultimately ensuring that their reagents prove successful on another manufacturer’s clinical chemistry analyser.

Benefits of open channel

The main benefit to laboratories in introducing open channel reagents is the ability to expand their test menu without expanding their laboratory, meaning there is no need to purchase additional equipment or analysers.

Many laboratories will be outsourcing or sending tests to a reference lab. This obviously has cost implications. By bringing the test in-house laboratories can make significant savings in both cost and turnaround time.

For some markers, although instrument manufacturers might offer the test it might not always be the most superior or the best method. Open channel or third-party reagents can sometimes offer a more accurate or superior method ultimately improving the accuracy of patient testing. This will be especially important to private laboratories in which the public are paying for this service. It also helps private labs stand out from their competition.

Obstacles to open channel suppliers

Despite the many benefits of open channel reagents there can be some challenges or obstacles to implementing this type of reagent.  For example, the packaging may not be compatible with the laboratory’s specific analyser, meaning an extra step for laboratory staff and the need to pour the reagent into a component suitable for the analyser. These obstacles in most cases can be easily overcome and the benefits often outweigh the challenges.

Considerations

If a lab is considering introducing an open channel supplier, there are a few things to consider and evaluate. Firstly, laboratories should ensure whether the clinical chemistry analyser is locked or requires special packaging. In some instances, the instrument is provided with the benefit of fully open channel capabilities, however some manufacturers require to be contacted in order to implement this functionality.

How Randox can help

At Randox we can introduce cost savings for your laboratory and reduce the risk of errors occurring, ultimately ensuring confidence in patient test results whilst reducing time and labour.

Randox Reagents offer an extensive range of third party reagents that can be used on a wide range of clinical analysers, most of which are liquid ready-to-use. At Randox we are one of the few suppliers offering niche tests including sdLDL, Adiponectin and Cystatin C. All diagnostic reagents are presented in bottles which fit easily onto your analyser avoiding the need to pour the reagents into dedicated bottles. A wide range of validated analyser applications are available to ensure ease of programming and confidence in results.

The vision of Randox is one of ambition, innovation and commitment to improving health worldwide. We firmly believe that the healthcare of tomorrow depends on the innovations developed today. As a world leader in the in-vitro diagnostics industry with over 35 years’ experience, Randox products offer clinicians and physicians the most comprehensive insight into patient diagnosis allowing for more effective disease management and treatment.

Want to know more?

Contact us or download our Reagents overview brochure

Related Products

Randox Reagents Homepage

Randox Reagents Resource Hub

Specific Proteins Panel


Drugs of Abuse – A Global Pandemic

4th September 2019

Drugs of Abuse – A Global Pandemic

The prevalence of drug addiction and abuse across the globe has become a growing concern. It is currently estimated that 71 million people use drugs of abuse with around 166,000 direct deaths occurring from drug use in 2017.

The WHO (World Health Organisation) estimate that 11 million people inject drugs across the globe, of which 1.3 million are living with HIV, 5.5 million with hepatitis C, and 1 million with both HIV and hepatitis C. In addition to infectious disease, long term drug abuse increases the risk of several cancers, cardiovascular effects, respiratory effects, gastrointestinal effects, kidney & liver damage and mental health issues.

The abuse of drugs is one of the most pressing issues in the USA and other countries globally. Drug abuse not only affects the individual, but can also have far-reaching consequences that affect family, employment, personal health, health care systems, local communities, and society as a whole.

Global Drug Abuse – The buzz that keeps on going!

> Misuse of illicit drugs affects society through secondary costs incurred such as crime, reduced productivity at work, and health care expenses.

> Substance abuse costs the US health care system about $11 billion, with overall costs reaching $193 billion.

> Substance abuse and addiction also affects other areas of life leading to broken families, destroyed careers, death due to negligence or accident, domestic violence, physical abuse and child abuse.

> Drug abuse and addiction changes the chemistry of your brain. The longer an individual abuses drugs, the more damage is caused, making it more difficult to return to ‘normal’ during drug rehabilitation.

> Treating and tackling drug addiction is a challenge. As drug treatment and health services continue to fall short, there is an increased need to continuously adapt drug detection and analysis.

Randox laboratories are at the forefront, aiding the fight against drugs of abuse with a comprehensive range of 10 drugs of abuse assays including several stimulants, sedatives and opioids available to run on Randox’s very own clinical chemistry analysers, the RX series. To find out now how Randox is helping to tackle the ongoing prevalence of drugs of abuse click here or buy directly from the Randox Online Store.

About Randox Laboratories

    As a world leader in the in-vitro diagnostic industry with over 35 years’ experience, Randox is leading the charge in moving from a one-size-fits-all approach towards decisions, practices and products tailored to the needs of the individual.  This innovative approach to diagnostics has facilitated the development of revolutionary products designed specifically to enhance a patients’ quality of life.

    Want to know more?

    Contact us or visit our Drugs of Abuse pages to learn more.

    Related Products

    RX Overview

    Randox Reagents

    Therapeutic Drugs Monitoring

    • References


    Randox Reagents Resource Hub

    Resource Hub | Reagents

    • Brochures
    • Educational Items
    • Scientific Articles
    • Press Releases
    • Scientific Posters
    • Blogs
    • Infographics
    • Videos
    • Webinars
    Adiponectin Brochure

    Adiponectin

    Antioxidants Brochure

    Antioxidants

    Cardiology & Lipid Testing Brochure

    Cardiology & Lipid Testing

    Diabetes Portfolio Brochure

    Diabetes Portfolio

    Reagents Brochure

    Reagents Brochure

    sdLDL-C Flyer

    sdLDL-C

    sdLDL-C Flyer

    sdLDL-C (USA ONLY)

    Specific Proteins Brochure

    Specific Proteins

    Superior Performance & Unique Tests

    Total Bile Acids Flyer

    Total Bile Acids (5th Generation)

    Veterinary Diagnostic Solutions Brochure

    Veterinary Diagnostic Solutions

    International Brochures

    Download our brochures in other languages

    The Role of Adiponectin in Obesity and its Clinical Utility in Obesity-Associated Health Concerns

    Cystatin C Whitepaper

    Early Risk Assessment of Renal Impairment using the Biomarker Cystatin C

    sdLDL-C - Size Matters: The True Weight of Risk in Lipid Profiling

    Total Bile Acids Whitepaper

    Total Bile Acids: The Importance of Fifth Generation Tests

    APOLIPOPROTEIN ARTICLE SERIES: ISSUE 4

    APOLIPOPROTEIN ARTICLE SERIES: ISSUE 3

    APOLIPOPROTEIN ARTICLE SERIES: ISSUE 2

    APOLIPOPROTEIN ARTICLE SERIES: ISSUE 1

    MOVING ON FROM FRIEDEWALD

    DELVING DEEPER INTO THE IMPORTANCE OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE

    Adiponectin, APFCB, 2013

    Adiponectin, IFCC WorldLab, 2014

    Glucose Hexokinase, AACC, 2014

    H-FABP IT, EuroMedLab, 2011

    Haptoglobin, AACC, 2014

    Lp(a), AACC, 2012

    sdLDL-C, Heart UK, 2010

    sPLA2-IIA, AACC, 2014

    TAS, SFRR, 2007

    Triglycerides, AACB, 2014

    World Kidney Day 2020

    World Kidney Day 2020

    World Diabetes Day 2019

    World Health Day 2018

    12 Days of HDL3-C

    World Health Day 2016

    Ask the Expert | R&D Scientist | Team Reagents

    H-FABP | Myocardial Ischemia | Randox Reagents

    Small Dense LDL-C and Cardiovascular Disease | Ernst J. Schaefer

    Clinical Considerations in Evaluating Lipid Risk Beyond LDL-C | Christie M Ballantyne, MD

    Want to know more?

    Contact us or visit the Reagents International Resource Hub


    RX Series Resource Hub

    RX series | Resource Hub

    • Brochures
    • International Brochures
    • Educational
    • Flyers
    • International Flyers
    • Videos
    • Blogs
    • Scientific Posters
    • Testimonials

    RX series Overview

    RX misano

    RX monaco

    RX daytona +

    RX imola

    RX modena

    RX series Overview

    Discover more about the RX series

    Espanoi RX series Overview

    Espanoi RX misano

    Espanoi RX monaco

    Espanoi RX daytona +

    Espanoi RX imola

    Espanoi RX modena

    Polski RX series overview

    Polski RX misano

    Polski RX monaco

    Polski RX daytona +

    Polski RX imola

    Polski RX modena

    Francais RX series overview

    RX modena, for measurement of Lipid Profile Tests

    RX modena, Direct HbA1c Testing Capabilities

    Measurement of Cystatin C on the RX series

    Measurement of Lipoprotein (a) on the RX monaco

    RX series overview

    RX misano

    RX modena

    RX series Veterinary Diagnostics

    RX series Direct HbA1c Testing Capabilities

    Polski RX series overview

    Francais RX misano

    Francais RX modena

    RX series - Offering the World's Largest Clinical Chemistry Test Menu

    RX series racetrack video

    RX daytona +

    RX imola

    RX modena

    RX series logo rebrand

    RX misano education & research

    Direct Measurement of HbA1c in Whole Blood on the RX daytona+, RX imola & RX modena

    Customer Testimonial | Adrian Cudmore NHS

    Customer Testimonial | DR Caje Moniz NHS

    Customer Testimonial | Dr Rosa Sierra Amor

    Customer Testimonial | Dr Bianca Thakkar

    Customer Testimonial | Dr. Anil Shah

    Customer Testimonial | Dr Pragati Desai

    Customer Testimonial | Dr Pramod Ingale

    Customer Testimonial | Dr Rajeev Mehta

    Customer Testimonial | Dr Simple Bhuptani

    Customer Testimonial | Dr SM Patel

    Customer Testimonial | Dr Trupti Patel

    Customer Testimonial | Dr A Vahed Mulla


    Tackling Worldwide Drugs of Abuse

    Throughout November, we’ve been highlighting how the Randox clinical teams – Randox Rx series, Randox Reagents and Randox QC – are aiding the fight against drugs of abuse.

    Drugs of Abuse are a growing problem worldwide and represent a significant burden to healthcare systems as well as creating problems in an individual’s lifestyle. It has been estimated by the WHO (World Health Organisation) that 31 million people globally suffer from drug use disorders and 3.3 million deaths each year are linked to the abuse of both drugs and alcohol.

    The abuse of drugs is one of the most pressing issues in the United States of America. Drug abuse not only affects the individual, but also can have far-reaching consequences that affect family, employment, personal health, health care systems, local communities, and society as a whole.

    • Misuse of illicit drugs affects society through secondary costs incurred such as crime, reduced productivity at work, and health care expenses.
    • Substance abuse costs the US health care system about $11 billion, with overall costs reaching $193 billion.
    • Substance abuse and addiction also affects other areas of life and can cause broken families, destroyed careers, death due to negligence or accident, domestic violence, physical abuse and child abuse.
    • Drug abuse and addiction changes the chemistry of your brain. The longer you use your drug of choice, the more damage is caused and it becomes more difficult to return to ‘normal’ during drug rehabilitation.
    • In 2013, 22.7 million Americans needed treatment for a substance use disorder – almost 9% of the population over the age of 12. Only about 2.5 million received treatment as a specialist facility with 20% of admissions for opiate addication treatment and 17% for the treatment of marijuana abuse.

    To find out more about how Randox is helping in the fight against Drugs of Abuse, please visit https://www.randox.com/drugs-of-abuse/ or for more information about Randox RX, Randox Reagents or Randox QC, please email marketing@randox.com.

     

     


    November focus: Drugs of Abuse

    Throughout November, the Randox clinical teams – Randox Reagents, Randox Rx series and Randox QC – will be highlighting how the Randox product range can be utilised to allow for the most accurate analysis of Drugs of Abuse, with a particular focus placed with the Evidence MultiSTAT. The Evidence MultiSTAT is a fast, fully automated and versatile immunoanalyser that enables on-site detection of up to 21 Drugs of Abuse from a single sample of oral fluid, urine or blood.

    Drugs of Abuse are a growing problem worldwide and represent a significant burden to healthcare systems as well as creating problems in an individual’s lifestyle.  It has been estimated by the WHO (World Health Organisation) that 31 million people globally suffer from drug use disorders and 3.3 million deaths each year are linked to the abuse of both drugs and alcohol.

    Randox have reacted to this growing concern and are now a world leader in the Drugs of Abuse testing field.  Our product range currently comprises classical, prescription and synthetic drugs.

    The Evidence MultiSTAT offers a simple drug screening solution to those who have little or no knowledge of laboratory procedures. As an extremely versatile desktop analyser, it is ideally suited to a variety of settings including both the clinical laboratory and the emergency room.

    Randox Reagents – Drugs of Abuse Assays

    In order to assist in dealing with the ongoing burden of substance abuse, Randox Reagents offer a comprehensive range of ten assays to test for some of the top most commonly-abused substances including alcohol, methamphetamines, cocaine, methadone, cannabis, benzodiazepines, barbiturates, EDDP and ecstasy and opiates.  The Randox Drugs of Abuse assays are liquid, ready-to-use for increased efficiency and applications are available for over 30 different analysers.

    RX Series – Toxicology testing

    Renowned for quality and reliability, the RX series range of clinical chemistry analysers boasts a world-leading test menu comprising of both therapeutic drugs and Drugs of Abuse.  Our toxicology range comprises amphetamines, barbiturates, benzodiazepines, cannabinoids, cocaine metabolite, ecstasy, EDDP, ethanol, methadone and opiates. The RX series range of clinical chemistry analysers ensures a high degree of accuracy with a wide range of testing throughputs to suit all laboratories, big or small.

    RIQAS Urine Toxicology Programme

    Designed to monitor the performance of 20 Drugs of Abuse tests in urine, our RIQAS urine toxicology EQA program is suitable for both qualitative and quantitative methods of analysis.  As the largest EQA scheme in the world, access to large peer groups is guaranteed.  Additional benefits include; monthly analysis, user-friendly reports allowing at-a-glance performance assessment, ability to register up to five instruments per programme and cost savings via our unrivalled consolidation.

    For more information about Randox RX, Randox Reagents or Randox QC, please email marketing@randox.com.

     

     


    Randox Reagents International Resource Hub

    International Resource Hub | Reagents

    • 中国
    • Español
    • Français
    • Polski
    • Português
    • Slovenský
    • 한국어

    Reagents Quick Reference Guide

    Cardiology & Lipid Testing

    Cardiology & Lipid Testing

    HDL3 Cholesterol

    High Performance & Unique Tests

    Reagents Quick Reference Guide

    Cardiology & Lipid Testing

    Diabetes Portfolio

    High Performance & Unique Tests

    TxBCardio

    Veterinary Diagnostic Solutions

    High Performance & Unique Tests

    sdLDL-C Flyer

    Cystatin Whitepaper

    sdLDL-C Whitepaper

    Cardiology & Lipid Testing

    Cystatin C Whitepaper

    Diabetes Portfolio

    High Performance & Unique Tests

    Homocysteine Flyer

    sdLDL-C Whitepaper

    Specific Proteins

    TBA Whitepaper

    Total Bile Acids Whitepaper

    Antioxidants


    Iron Deficiency Anaemia during Pregnancy

    On a global scale, 1.62 billion people are affected by anaemia which is equivalent to 24.8% of the population . According to a review carried out by WHO of various national surveys, anaemia affects approximately 42% of pregnant women worldwide and it is also estimated that at least 50% of all anaemia cases are due to iron deficiency.

    Anaemia caused by iron deficiency is usually expected during pregnancy. This is due to several reasons: the increased demand for iron by a pregnant woman’s body from increased total blood cell volume, requirements of the foetus and placenta as well as mass blood loss during labour₂. Although iron cost is unbalanced by the lack of loss of menstrual blood during pregnancy, the net cost is still high enough that iron recommendations are higher than in non-pregnant women. Also, iron is critical during pregnancy considering its involvement in foetal growth: 600-800mg of iron is required during pregnancy with around 300mg needed just for the foetus, a minimum of 25mg for the placenta and almost 500mg due to the increase in volume of red blood cells. ₃

    Iron deficiency is the most common micronutrient deficiency in pregnant women leading to iron deficiency anaemia if left untreated. However, iron deficiency can be difficult to measure in some populations due to the lack of availability of field-specific biomarkers. For example, anaemia can affect up to 56% of pregnant women in developing countries, which suggests a high prevalence of iron deficiency anaemia: around 25%. In settings with endemic malaria, such as certain countries in Africa, the number of pregnant women with anaemia is much higher: around 65%.

    There are various factors that may increase the risks of iron deficiency anaemia. For example, a diet influenced by religious beliefs can cause a lack of iron in the diet, such as vegetarianism which is common in countries such as India where religious beliefs dictate this. Iron levels can also be affected by consumption of nutrients which inhibit proper absorption of iron, such as calcium or ones that promote iron absorption, such as vitamin C. Other circumstantial risks include infections, multiple pregnancies and adolescent pregnancy while socioeconomic factors and access to healthcare mean some women won’t have access to anaemia control programs, iron supplements or even access to information about iron deficiency anaemia during pregnancy.

    To prevent iron deficiency, international guidelines state that iron supplementation to manage iron deficiency is recommended during pregnancy. ₄ However, this is not always available, especially in developing countries.

    Iron deficiency anaemia during pregnancy can cause several complications for the mother including:

    • Increased fatigue
    • Short-term memory loss
    • Decreased attention span
    • Increased pressure on the cardiovascular system due to insufficient haemoglobin and blood oxygen levels
    • Lower resistance to infections
    • Reduced tolerance to significant blood loss and surgical implications during labour.

    As expected, neonates with mothers who suffered from iron deficiency anaemia during pregnancy will also be confronted with risks and, even if iron deficiency is only mild to moderate, can result in a premature birth, complications with foetal brain development, low birth weight and even foetal death. Additionally, it has been proven that cognitive and behavioural abnormalities can be seen in children for up to ten years after iron insufficiency in the womb.

    Randox Soluble Transferrin Receptor (sTfR) Reagent

    Randox Reagents offer a Soluble Transferrin Receptor assay to expand upon our current iron testing offering.

    In iron deficiency anaemia, soluble transferrin receptor levels are significantly increased, however, remain normal in acute phase conditions including: chronic diseases and inflammation.  As such, sTfR measurements are useful in the differential diagnosis of anaemia: anaemia of chronic disease or iron deficiency anaemia.

    In iron deficiency anaemia, increased sTfR levels have also been observed in haemolytic anaemia, sickle cell anaemia and B12 deficiency.

    The benefits of the Randox Soluble Transferrin Receptor (sTfR) Reagent include:

    • Latex enhanced immunoturbidimetric method facilitating testing on biochemistry analysers and eliminating the need for dedicated equipment.
    • Liquid ready-to-use reagents for convenience and ease-of-use
    • Stable to expiry date when stored at +2 to +8 °C
    • Excellent measuring range of 0.5 – 11.77mg/L, comfortably detecting levels outside of the normal health range of 0.65 – 1.88mg/L
    • Excellent correlation coefficient of r=0.977 when compared against other commercially available methods
    • Applications available detailing instrument-specific settings for a wide range of clinical chemistry analysers

    Find out more at: https://www.randox.com/stfr/

    References:

    1. de Benoist B et al., eds.Worldwide prevalence of anaemia 1993-2005WHO Global Database on Anaemia Geneva, World Health Organization, 2008.
    2. Harvey et al, Assessment of Iron Deficiency and Anemia in Pregnant Women: An Observational French Study, Women’s Health, Vol 12 Issue 1, 2016
    3. Burke et al, Identification, Prevention and Treatment of Iron Deficiency during the First 1000 Days, Nutrients, Vol 6 Issue 10, 2014
    4. Guideline: Daily Iron and Folic Acid Supplementation in Pregnant Women. World Health Organization; Geneva, Switzerland: 2012

    If you are a clinician or laboratory who are interested in running assays to test iron status, Randox offer a range of assays, including: Iron, Total Iron-Binding Capacity (TIBC), Transferrin and Ferritin .  These assays can be run on most automated biochemistry analysers.

    Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers. Contact us to enquire about your specific analyser.

    For more information, visit: https://www.randox.com/stfr / or email: reagents@randox.com 


    World Heart Day 2018 – Randox Reagents

    Cardiovascular disease (CVD) is the number one cause of death globally and more people die annually from CVD than any other disease state. On World Heart Day 2018, Randox Reagents are committed to developing niche and superior performance assays for the early detection of CVD risk with the hope to change this statistic and improve the heart health of millions worldwide.

    There are a number of influencing factors that can lead to a patient experiencing a cardiovascular event. The risk factors for this multifactorial disease include: genetic predisposition, age, gender, smoking, hypertension, stress, dietary habits and physical inactivity. Little evidence exists explaining the mechanism of the Apolipoproteins in the body and their contribution to the causes of some of these cardiac diseases.

    Apolipoprotein E

    Apolipoprotein E (Apo E) is a lipid transport and signalling protein found in the blood which is synthesized mostly by the liver. Apo E has been found to have many roles in the body including the promotion of antiatherogenic properties. Essentially the main function of Apo E is to act as a ligand to the LDL receptor. This relationship plays a critical role in metabolism by promoting cellular uptake of lipoproteins. Through this process Apo E acts as a major component of overall plasma cholesterol homeostasis which facilitates the hepatic uptake of lipoproteins by binding to their receptors. It works to stabilise the equilibrium of cholesterol in the blood by transporting the cholesterol between cells preventing platelet aggregation. Apo E deficiency can influence the plasma concentration and metabolic destination of LDL creating an increased risk of CVD.

    Apolipoprotein C-III

    Apolipoprotein C-III is another apolipoprotein found in the circulatory system. Its metabolic actions have been found to be actively different to ApoE. The Apo C-III has been found to prevent binding of VLDL cellular receptors resulting in the conversion of VLDL to LDL rather than promoting the clearance of the circulatory system. In addition, it specifically and directly encourages proatherogenic changes in monocytes and endothelial cells. Research has found that the plasma concentration of LDL with Apo C-III strongly predicts the incidence of recurrent cardiovascular events.

    Working together to lower CVD Risk

    The conflicting roles of Apo E and Apo C-III in the circulatory system has created interest amongst researchers and has raised the question ‘Could the ApoE content of LDL Cholesterol with Apo C-III reduce the proatherogenic nature of Apo C-III reducing a patient’s risk of a CVD event?’.

    In fact, studies have now found that the presence of ApoE is associated with lower atherogenicity of LDL Cholesterol containing Apo C-III.  The abundance ApoE relative to the abundance of LDL Cholesterol with Apo C-III is a protective factor against coronary heart disease. This relationship is further supported by the antagonistic relationship between the two apolipoproteins. The idea that Apo E may be able to effectively protect against the effects of the combination of LDL Cholesterol with Apo C-III is important to consider due to their strong links with CVD.

    The Randox Apolipoprotein E and Apolipoprotein C-III reagent allows for prompt and accurate diagnosis of Apolipoprotein levels, an influencing factor in cardiovascular disease.

    The Randox Apolipoprotein E reagent

    The benefits of the Randox Apo E assay includ:

    • Excellent working reagent stability when stored at +2 to +8 ̊C
    • A wide measuring range of 1.04 -12.3 mg/dl enabling the comfortable detection of levels outside of the health range, 2.7-4.5 mg/dl
    • Liquid ready-to-use reagent for convenience and ease-of-use
    • Immunoturbidimetric method

    The Randox Apolipoprotein C-III reagent

    The key benefits of the Randox C-III assay include:

    • Liquid ready-to-use reagent for convenience and ease-of-use
    • Excellent Linearity of 21.7 mg/dl. The approximate normal upper limit for Apo CIII is 9.5 mg/dl therefore the Randox assay will comfortably detect elevated, potentially harmful levels of Apo C-III
    • Limited interference from Bilirubin, Haemoglobin, Intralipid and Triglycerides for truly accurate results
    • Applications are available detailing instrument-specific settings for a wide range of clinical chemistry analyzers
    • Immunoturbidimetric method

    References

    1. Apolipoprotein E in VLDL and LDL with Apolipoprotein C-III is Associated with a Lower Risk of Coronary Heart Disease. Mendivil, Carlos, et al. s.l. : Journal of the American Heart Association , 2013.

    If you are a cardiologist, clinician or laboratory who are interested in running assays for cardiovascular disease, Randox offer a range of high-quality routine and niche assays including: Adiponectin, Lp(a), H-FABP and HDL3, which can be used to diagnose conditions commonly affecting the heart.  These assays can be run on most automated biochemistry analysers.

    Instrument Specific Applications (ISA’s) are available for a wide range of biochemistry analysers. Contact us to enquire about your specific analyser.

    For more information, visit: https://www.randox.com/apolipoprotein-e / or email: reagents@randox.com  


    Request a meeting
    ×
    Make an Enquiry - RX series
    ×
    Make an Enquiry - Reagents
    ×
    Kit Insert Request - Reagents
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    ×
    Kit Insert Request - Reagents
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    ×
    Make an Enquiry - Reagents
    ×
    Make an Enquiry - Quality Control
    ×
    Make an Enquiry - RIQAS
    ×
    Make an Enquiry - RIQAS
    ×
    Make an Enquiry - Quality Control
    ×
    Make an Enquiry
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    ×
    Make an Enquiry - Biochip
    • This field is for validation purposes and should be left unchanged.
    ×
    Make an Enquiry - Molecular
    • Signing up to our mailing list is quick and easy. We do not wish to send you any spam or junk email, therefore, you can expect to receive mailshots including new product launches and updates, market trends, attendance at key industry events and much more. Randox Laboratories promise never to sell your data and we will keep all your details, safe and secure. Read more in our Privacy Policy.
    • This field is for validation purposes and should be left unchanged.
    ×
    Make an Enquiry - Future Diagnostics
    ×
    Make an Enquiry - RX series (Product)